{"entity":{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","aka":[],"tldr":"mAbxience Research S.L. is a Spain-based biotechnology company running 2 late-stage cancer trials in melanoma and non-small-cell lung cancer.","summary":"mAbxience Research S.L., based in Madrid, Spain, is a biotechnology company. mAbxience is a vertically integrated biopharmaceutical company that develops biosimilars and operates an independent contract development and manufacturing organisation (CDMO) platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in melanoma and non-small-cell lung cancer. The largest, NCT06687369 (A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)), plans to enrol 726 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.mabxience.com"},{"label":"ClinicalTrials.gov: trials led by mAbxience Research S.L.","url":"https://clinicaltrials.gov/search?lead=mAbxience%20Research%20S.L."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06687369","nct07221734"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Madrid","country":"ES","companyType":"biotech","website":"https://www.mabxience.com","investors":[],"funding":[]},"route":"/companies/mabxience-research-s-l/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"trial":[{"id":"nct06687369","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L","route":"/trials/nct06687369/"},{"id":"nct07221734","kind":"trial","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","route":"/trials/nct07221734/"}]}}